Drug
Finafloxacin clinical trials
Includes 1 study of Finafloxacin hydrochloride.
- studies test it
- 10
- open now
- 0
- in phase 3
- 2
- first study started
- 2007
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 2012 (4)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 2 |
| 2012 | 4 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 3
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
MerLion Pharmaceuticals GmbH (7) · Alcon Research (3)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses finafloxacin is read from its arms, and is right about nine times in ten.
Testing it · 10
- Effect of Age and Gender on the PK and Tolerability of FinafloxacinCompletedPhase 1MerLion Pharmaceuticals GmbHNCT01904162Written as 400 mg finafloxacin (2 x 200 mg tablets)
- Finafloxacin for the Treatment of cUTI and/or Acute PyelonephritisCompletedPhase 2MerLion Pharmaceuticals GmbHNCT01928433Written as Finafloxacin 800 mg i.v. once daily
- Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of FinafloxacinCompletedPhase 1MerLion Pharmaceuticals GmbHNCT01907867Written as Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days
- Pharmacokinetic Study of AL-60371 Otic Suspension in Pediatric Subjects Following Tympanostomy Tube SurgeryWithdrawnPhase 1Alcon ResearchNCT01908764Written as AL-60371 otic suspension
- Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis ExternaCompletedPhase 3Alcon ResearchNCT01535599Written as AL-60371, 0.3% Otic Suspension
- Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis ExternaCompletedPhase 3Alcon ResearchNCT01535560Written as AL-60371, 0.3% otic suspension
- Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy SubjectsCompletedPhase 1MerLion Pharmaceuticals GmbHNCT01910883Written as Finafloxacin i.v. solution 200 mg
- Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected PatientsCompletedPhase 2MerLion Pharmaceuticals GmbHNCT00723502Written as Finafloxacin + Amoxicillin
- Finafloxacin 300 mg Twice a Day (b.i.d.) Versus Ciprofloxacin 250 mg Twice a Day (b.i.d) in Patients With Lower Uncomplicated UTI (uUTI)CompletedPhase 2MerLion Pharmaceuticals GmbHNCT00722735Written as Finafloxacin
- First Time in Man Study of Finafloxacin HydrochlorideCompletedPhase 1MerLion Pharmaceuticals GmbHNCT00483158Written as Finafloxacin hydrochloride
Codes
What other systems call finafloxacin · ClinicalTrials.gg INT005881
- MeSH (NLM) C560572finafloxacinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) D26OSN9Q4RFINAFLOXACINConfirmed FDA, NLM, Wikidata
- RxNorm 1598641Confirmed FDA, Wikidata
- Wikidata Q21011229finafloxacinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C80638FinafloxacinOne source FDA
- DrugBank DB09047One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C560572 | finafloxacin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | D26OSN9Q4R | FINAFLOXACIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1598641 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21011229 | finafloxacin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C80638 | Finafloxacin | One source FDA |
| DrugBank | DB09047 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.